Kroon S
Department of Dermato-Venereology, Bispebjerg Hospital, University of Copenhagen, Denmark.
Semin Dermatol. 1990 Jun;9(2):133-40.
The link between genital ulcers and transmission of the human immunodeficiency virus highlights the need of prevention and treatment of genital herpes. Although a diversity of specific and unspecific drugs have been tested on effects toward herpes simplex virus types 1 and 2, only one antiviral drug, acyclovir, have proven safe and efficacious on some aspects of the disease. The drug has a marked effect on first episodes of herpes genitalis, but the effect on recurrences are less pronounced because viral replication is of shorter duration. Selection of patients for antiviral treatment involves considerations of immune status, the risk of neonatal transmission for pregnant women, and the severity of local and systemic symptoms, incidence of prodromal symptoms, and most importantly, recurrence rates, because this signals the psychological impact of the disease. The main goals of any herpes treatment--to eradicate latent infection in primary as well as recurrent disease--are not achieved by any known antiviral or immunomodulatory drug.
生殖器溃疡与人类免疫缺陷病毒传播之间的联系凸显了预防和治疗生殖器疱疹的必要性。尽管已经对多种特异性和非特异性药物针对1型和2型单纯疱疹病毒的作用进行了测试,但只有一种抗病毒药物阿昔洛韦在该疾病的某些方面被证明是安全有效的。该药物对生殖器疱疹的初次发作有显著效果,但对复发的效果不太明显,因为病毒复制持续时间较短。选择抗病毒治疗的患者需要考虑免疫状态、孕妇新生儿传播风险、局部和全身症状的严重程度、前驱症状的发生率,最重要的是复发率,因为这表明了该疾病的心理影响。任何疱疹治疗的主要目标——根除原发性和复发性疾病中的潜伏感染——都无法通过任何已知的抗病毒或免疫调节药物实现。